Phase II clinical trial of cis dichlorodiammine platinum (Cis DDP) in metastatic brain tumors

Kolarić, K; Roth, A; Jelicić, I; Matković, Anto

doi:10.1007/bf00406247

Cited by 27 publications

(12 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Platinum agents are www.TheOncologist.com ©AlphaMed Press 2016 Sharma not new to the treatment of breast cancer. In the 1980s, cisplatin was evaluated in advanced breast cancer in two phase II studies and demonstrated significant single-agent frontline activity, with response rates in the range of 50%-54% [59,60]. Because of its toxicity, cisplatin was subsequently abandoned and replaced by other active agents with more favorable toxicity profiles (taxanes, fluoropyridines).…”

Section: Role Of Platinum Agentsmentioning

confidence: 99%

Biology and Management of Patients With Triple-Negative Breast Cancer

2016

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) accounts for 15% of all breast cancers and is associated with poor long-term outcomes compared with other breast cancer subtypes. Because of the lack of approved targeted therapy, at present chemotherapy remains the mainstay of treatment for early and advanced disease. TNBC is enriched for germline BRCA mutation, providing a foundation for the use of this as a biomarker to identify patients suitable for treatment with DNA-damaging agents. Inherited and acquired defects in homologous recombination DNA repair, a phenotype termed "BRCAness," may be present in a large proportion of TNBC cases, making it an attractive selection and response biomarker for DNAdamaging therapy. Triple-negative breast cancer is a diverse entity for which additional subclassifications are needed.Increasing understanding of biologic heterogeneity of TNBC has provided insight into identifying potentially effective systemic therapies, including cytotoxic and targeted agents. Numerous experimental approaches are under way, and several encouraging drug classes, such as immune checkpoint inhibitors, poly(ADP-ribose) polymerase inhibitors, platinum agents, phosphatidylinositol-3-kinase pathway inhibitors, and androgen receptor inhibitors, are being investigated in TNBC. Molecular biomarker-based patient selection in early-phase trials has the potential to accelerate development of effective therapies for this aggressive breast cancer subtype. TNBC is a complex disease, and it is likely that several different targeted approaches will be needed to make meaningful strides in improving the outcomes. The Oncologist 2016;21:1050-1062Implications for Practice: Triple-negative breast cancer (TNBC) is an aggressive subtype that is associated with poor outcomes.This article reviews clinical features and discusses the molecular diversity of this unique subtype. Current treatment paradigms, the role ofgermline testing, and platinum agents in TNBC are reviewed. Results and observations from pertinent clinical trials with potential implications for patient management are summarized.This article also discusses the clinical development and ongoing clinical trials of novel promising therapeutic agents in TNBC.

show abstract

Section: Role Of Platinum Agentsmentioning

confidence: 99%

Biology and Management of Patients With Triple-Negative Breast Cancer

2016

View full text Add to dashboard Cite

show abstract

“…In general, the response of lung cancer to CDDP therapy seems to vary from case to case, depending on the sensitivity of the individual's cancer cells to this drug. Regarding chemotherapy of metastatic brain tumor derived from lung cancer, treatment with CDDP alone has been found to be efficacious in three separate studies [8,17,18]. Kolaric et al [8] observed a complete response to intravenous CDDP treatment in one of eight patients, partial response in two, disease stabilization in one, and progression in four, that is, an overall a positive response rate of 3/8.…”

Section: Discussionmentioning

confidence: 97%

“…Regarding chemotherapy of metastatic brain tumor derived from lung cancer, treatment with CDDP alone has been found to be efficacious in three separate studies [8,17,18]. Kolaric et al [8] observed a complete response to intravenous CDDP treatment in one of eight patients, partial response in two, disease stabilization in one, and progression in four, that is, an overall a positive response rate of 3/8. Lehane and colleagues [17] reported a complete response to intra-arterial CDDP administration in one of eight patients, partial response in five, and no response in two, that is, an overall response rate of 6/8.…”

Section: Discussionmentioning

confidence: 97%

“…Two studies [1,2] have demonstrated the efficacy of CDDP as a single agent in the treatment of lung cancer, however, several others [3][4][5][6] have suggested that CDDP is relatively ineffective when used alone against this disease. Both primary malignant gliomas and metastatic brain tumors are usually treated with this drug, and its effects [7][8][9] have been reported. This study was undertaken to evaluate the effects of CDDP on brain tumors that had metastasized from lung cancer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cis-diamminedichloroplatinum (CDDP) therapy for brain metastasis of lung cancer

et al. 1993

View full text Add to dashboard Cite

Parenchymal brain tumors, which were metastases of primary lung cancer, were surgically removed from 25 patients. During the operation, patients were administered (intravenous or intracarotid) 100 mg/sq m of cis-diamminedichloroplatinum (CDDP) and postoperatively, they received intravenous CDDP at 3-month intervals for 1 year. The results of this mode of treatment were compared with those obtained in 25 patients who underwent the same surgery but received other anticancer agents and in 39 patients who received no postoperative chemotherapy. Patients in the CDDP-treated group survived much longer than both of the other treatment groups. In the CDDP, but not in the other two groups, survival was significantly longer in patients who had undergone resection of their lung tumors than in those who had not. The stage of lung cancer was not found to significantly influence survival time among CDDP-treated patients. Brain metastasis was the cause of death in 12% of the patients who received CDDP, in 16% those treated with other drugs, and in 26% of those who received no chemotherapy. The incidence of local and remote intracranial tumor recurrence, including meningeal carcinomatosis, was similar in the three groups. However, the mean interval from resection of the metastatic brain tumor to local or remote recurrence was longer in the CDDP-treated group than in the other two groups, and the 2-year-survival rate was significantly higher after CDDP administration. These results suggest that CDDP may be useful in the therapy of metastatic brain tumors derived from lung cancer.

show abstract

“…An overview of the 8 studies found in literature that included at least 10 breast cancer patients is given in table 1. Studies with less than 10 breast cancer patients [41][42][43] were excluded. The study by Cocconi et al [44] was excluded, because all patients were also reported in the larger follow-up publication [45].…”

Section: Clinical Trials For Chemotherapy In Breast Cancer Brain Metamentioning

confidence: 99%

Chemotherapy for Breast Cancer Brain Metastases

Fenner

Possinger²

2002

Oncol Res Treat

View full text Add to dashboard Cite

Breast cancer is the second most common cause of brain metastases, and 10–15% of patients develop clinically overt central nervous system disease. Radiotherapy is the standard treatment for patients with brain metastases. Surgical resection should be considered in patients with isolated brain metastasis and no extracranial disease. The role of chemotherapy in breast cancer brain metastases is not clearly defined; the results of the 8 trials found in the literature are reported. Most experience has been gained with the CMF (cyclophosphamide, methotrexate and fluorouracil) and PE (cisplatin and etoposide) regimens; here the median survival of 6 months is similar to radiotherapy. The blood-brain barrier, maintained by tight endothelial junctions and active transport mechanisms, is a major reason for the lower activity of most chemotherapeutic agents compared to other sites of metastatic disease. Most substances with good penetration of the blood-brain barrier have limited activity against breast cancer and some of the most active substances in breast cancer – including doxorubicine, the taxanes and trastuzumab – appear not to reach the central nervous system in sufficient concentrations. Approaches to overcome the blood-brain barrier are still experimental, and more research is clearly needed to identify chemotherapeutic agents both active in breast cancer and with good penetration of the blood-brain barrier. With the exception of patients with resectable brain metastases, danger of cranial herniation or poor general condition, chemotherapy should be offered to breast cancer patients with brain metastases that have progressive extracranial metastatic disease or relapse after radiotherapy.

show abstract

Phase II clinical trial of cis dichlorodiammine platinum (Cis DDP) in metastatic brain tumors

Cited by 27 publications

References 7 publications

Biology and Management of Patients With Triple-Negative Breast Cancer

Biology and Management of Patients With Triple-Negative Breast Cancer

Cis-diamminedichloroplatinum (CDDP) therapy for brain metastasis of lung cancer

Chemotherapy for Breast Cancer Brain Metastases

Contact Info

Product

Resources

About